Rigel Pharmaceuticals, Inc. - stock earnings
RIGL Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 7, 2024 AfterMarket | - / -0.0294000000 | - | - / 31.9 million | - |
RIGL Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 737000 USD | 35.8 million USD |
| 2023Q3 | -5.7 million USD | 28.1 million USD |
| 2023Q2 | -6.6 million USD | 26.9 million USD |
| 2023Q1 | -14.3 million USD | 26.1 million USD |
| 2022Q4 | 723000 USD | 51.3 million USD |
| 2022Q3 | -19.7 million USD | 22.4 million USD |
| 2022Q2 | -14.0 million USD | 29.8 million USD |
| 2022Q1 | -28.6 million USD | 16.7 million USD |
| 2021Q4 | -22.6 million USD | 20.4 million USD |
| 2021Q3 | -21.0 million USD | 21.5 million USD |
| 2021Q2 | -13.8 million USD | 26.3 million USD |
| 2021Q1 | 39.5 million USD | 81.0 million USD |
| 2020Q4 | -19.2 million USD | 18.5 million USD |
| 2020Q3 | -14.2 million USD | 18.4 million USD |
| 2020Q2 | -17.6 million USD | 16.0 million USD |
| 2020Q1 | 21.2 million USD | 55.8 million USD |
| 2019Q4 | -17.2 million USD | 15.4 million USD |
| 2019Q3 | -11.5 million USD | 20.9 million USD |
| 2019Q2 | -20.6 million USD | 10.4 million USD |
| 2019Q1 | -17.6 million USD | 12.6 million USD |
| 2018Q4 | 3.2 million USD | 37.9 million USD |
| 2018Q3 | -23.8 million USD | 4.9 million USD |
| 2018Q2 | -25.6 million USD | 1.8 million USD |
| 2018Q1 | -24.4 million USD | ? USD |
| 2017Q4 | -25.9 million USD | 3.6 million USD |
| 2017Q3 | -17.7 million USD | 900000 USD |
| 2017Q2 | -19.1 million USD | 3.6 million USD |
| 2017Q1 | -15.3 million USD | 3.6 million USD |
| 2016Q4 | -15.6 million USD | 3.0 million USD |
| 2016Q3 | -22.6 million USD | 3.8 million USD |
| 2016Q2 | -13.5 million USD | 8.6 million USD |
| 2016Q1 | -17.5 million USD | 5.0 million USD |
| 2015Q4 | -12.7 million USD | 8.5 million USD |
| 2015Q3 | -6.7 million USD | 13.0 million USD |
| 2015Q2 | -13.9 million USD | 5.2 million USD |
| 2015Q1 | -18.2 million USD | 2.2 million USD |
| 2014Q4 | -22.3 million USD | 8.3 million USD |
| 2014Q3 | -20.9 million USD | ? USD |
| 2014Q2 | -25.4 million USD | ? USD |
| 2014Q1 | -22.3 million USD | 5.8 million USD |
| 2013Q4 | -16.9 million USD | 5.8 million USD |
| 2013Q3 | -23.8 million USD | 1.4 million USD |
| 2013Q2 | -22.8 million USD | 1.4 million USD |
| 2013Q1 | -25.6 million USD | ? USD |
| 2012Q4 | -25.5 million USD | 2.3 million USD |
| 2012Q3 | -25.5 million USD | 1.5 million USD |
| 2012Q2 | -24.7 million USD | 1.5 million USD |
| 2012Q1 | -23.2 million USD | 750000 USD |
| 2011Q4 | -25.8 million USD | 395000 USD |
| 2011Q3 | -17.9 million USD | 4.4 million USD |
| 2011Q2 | -21.5 million USD | 395000 USD |
| 2011Q1 | -20.8 million USD | ? USD |
| 2010Q4 | -17.2 million USD | -125.0 million USD |
| 2010Q3 | 50.4 million USD | 72.3 million USD |
| 2010Q2 | 27.0 million USD | 49.5 million USD |
| 2010Q1 | -22.3 million USD | 3.3 million USD |
| 2009Q4 | -25.1 million USD | 750000 USD |
| 2009Q3 | -26.7 million USD | ? USD |
| 2009Q2 | -29.9 million USD | ? USD |
| 2009Q1 | -29.9 million USD | ? USD |
| 2008Q4 | -33.4 million USD | ? USD |
| 2008Q3 | -37.7 million USD | ? USD |
| 2008Q2 | -34.0 million USD | ? USD |
| 2008Q1 | -27.3 million USD | 8.0 million USD |
| 2007Q4 | -19.0 million USD | 8.0 million USD |
| 2007Q3 | -18.9 million USD | 2.0 million USD |
| 2007Q2 | -19.2 million USD | 2.0 million USD |
| 2007Q1 | -17.1 million USD | 2.6 million USD |
| 2006Q4 | -15.5 million USD | 3.1 million USD |
| 2006Q3 | -11.4 million USD | 6.1 million USD |
| 2006Q2 | -2.3 million USD | 14.3 million USD |
| 2006Q1 | -8.5 million USD | 9.9 million USD |
| 2005Q4 | -8.9 million USD | 6.0 million USD |
| 2005Q3 | -12.9 million USD | 3.3 million USD |
| 2005Q2 | -12.3 million USD | 4.6 million USD |
| 2005Q1 | -11.2 million USD | 2.6 million USD |
| 2004Q4 | -14.7 million USD | 1.1 million USD |
| 2004Q3 | -16.1 million USD | 659000 USD |
| 2004Q2 | -12.3 million USD | 1.5 million USD |
| 2004Q1 | -13.1 million USD | 1.5 million USD |
| 2003Q4 | -11.9 million USD | 2.1 million USD |
| 2003Q3 | -11.1 million USD | 2.1 million USD |
| 2003Q2 | -10.5 million USD | 2.3 million USD |
| 2003Q1 | -7.8 million USD | 4.5 million USD |
| 2002Q4 | -8.1 million USD | 3.7 million USD |
| 2002Q3 | -10.1 million USD | 3.7 million USD |
| 2002Q2 | -10.4 million USD | 4.3 million USD |
| 2002Q1 | -8.4 million USD | 4.1 million USD |
| 2001Q4 | -6.1 million USD | 4.8 million USD |
| 2001Q3 | -6.2 million USD | 4.2 million USD |
| 2001Q2 | -7.3 million USD | 3.1 million USD |
| 2001Q1 | -4.2 million USD | 3.2 million USD |
| 2000Q4 | -5.8 million USD | 3.2 million USD |
| 2000Q3 | -6.5 million USD | 3.3 million USD |
| 2000Q2 | -6.5 million USD | 3.3 million USD |
| 2000Q1 | -6.5 million USD | 3.3 million USD |
RIGL Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -25.1 million USD | 116.9 million USD |
| 2022 | -61.6 million USD | 120.2 million USD |
| 2021 | -17.9 million USD | 149.2 million USD |
| 2020 | -30.4 million USD | 108.6 million USD |
| 2019 | -66.5 million USD | 59.3 million USD |
| 2018 | -70.5 million USD | 44.5 million USD |
| 2017 | -78.0 million USD | 4.5 million USD |
| 2016 | -69.2 million USD | 20.4 million USD |
| 2015 | -51.5 million USD | 28.9 million USD |
| 2014 | -90.9 million USD | 8.3 million USD |
| 2013 | -89.0 million USD | 7.2 million USD |
| 2012 | -98.8 million USD | 2.3 million USD |
| 2011 | -86.0 million USD | 4.8 million USD |
| 2010 | 37.9 million USD | 125.0 million USD |
| 2009 | -111.5 million USD | 750000 USD |
| 2008 | -132.3 million USD | ? USD |
| 2007 | -74.3 million USD | 12.6 million USD |
| 2006 | -37.6 million USD | 33.5 million USD |
| 2005 | -45.3 million USD | 16.5 million USD |
| 2004 | -56.3 million USD | 4.7 million USD |
| 2003 | -41.2 million USD | 11.1 million USD |
| 2002 | -37.0 million USD | 15.8 million USD |
| 2001 | -23.8 million USD | 15.3 million USD |
| 2000 | -25.4 million USD | 13.2 million USD |
| 1999 | -12.4 million USD | 9.0 million USD |
RIGL
Price: $1.24
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.14 USD
P/E Ratio: -8.71
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 2.8 million
Ebitda: -17.7 millionMarket Capitalization: 214.0 million